Skip to main navigation Skip to search Skip to main content

Plasma nucleosome profiling reports on tumor burden and molecular subtypes in small cell lung cancer

  • Gavriel Fialkoff
  • , Nobuyuki Takahashi
  • , Israa Sharkia
  • , Jenia Gutin
  • , Nadav Hermoni
  • , Michael Nirula
  • , Rajesh Kumar
  • , Lorinc Pongor
  • , Samantha Nichols
  • , Linda Sciuto
  • , Kanak Parmar
  • , Parth Desai
  • , Priya Suresh
  • , Melissa Abel
  • , Rajaa El Meskini
  • , Myriam Maoz
  • , Yakir Rottenberg
  • , Shoshan Nevo
  • , Hovav Nechushtan
  • , Tamar Peretz
  • Diana Roame, Ayala Hubert, Jonathan E. Cohen, Azzam Salah, Mark Temper, Albert Grinshpun, Zoe Weaver-Ohler, Arun Rajan, Sr William Douglas Figg, Aviad Zick, Ronen Sadeh, Nir Friedman, Anish Thomas

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND. Small-cell lung cancer (SCLC) is an aggressive malignancy with a poor prognosis and marked transcriptional heterogeneity that may drive distinct therapeutic vulnerabilities. Clinical translation of molecular subtyping has been limited by restricted access to tumor biopsies, particularly at relapse. METHODS. We applied chromatin immunoprecipitation of cell-free nucleosomes carrying active histone modifications followed by sequencing (cfChIP-seq) to 441 plasma samples from individuals with advanced SCLC, other neuroendocrine carcinomas, or non-SCLC cancers, as well as from healthy controls. Plasma cfChIP-seq profiles were integrated with matched tumor transcriptomes from 73 samples, including 41 time-matched pairs. RESULTS. cfChIP-seq captured the epigenetic and transcriptional landscape of tumor-derived cell-free DNA (cfDNA), including SCLC tissue- and cell-of-origin signatures. A quantitative cfChIP-seq–derived SCLC score tracked radiographic tumor burden and was associated with prognosis. Signals at promoters of lineage-defining transcription factor genes, including ASCL1, NEUROD1, POU2F3, and ATOH1, correlated strongly with matched tumor RNA expression and supported noninvasive inference of SCLC transcriptional subtypes directly from plasma. CONCLUSION. Plasma cfChIP-seq provides a practical liquid biopsy platform for real-time assessment of tumor burden, tumor state, and molecular subtype in SCLC. These findings support further development of cfChIP-seq for precision monitoring and subtype-informed therapeutic stratification in SCLC.

Original languageEnglish
Article numbere202151
JournalJournal of Clinical Investigation
Volume136
Issue number19
DOIs
StatePublished - Oct 2026

Bibliographical note

Publisher Copyright:
© 2026, Fialkoff et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Plasma nucleosome profiling reports on tumor burden and molecular subtypes in small cell lung cancer'. Together they form a unique fingerprint.

Cite this